Suki

• Choose a cheaper self-service tool first when the requirement is only basic note generation. Freed offers a transparent limited-volume plan and trial; Suki’s current sales-led model creates more commercial uncertainty. (getfreed.ai)
• Do not proceed when your pilot shows no net time savings. A faster draft is irrelevant if editing and transfer exceed the time previously spent charting. (reddit.com)
• Do not standardize across a difficult specialty solely on the “100+ specialties” claim. Oncology feedback identifies a specific risk that should be tested, not generalized to every oncologist. (apps.apple.com)
• Consider dictation or another workflow for brief inpatient follow-ups. One firsthand user found ambient capture inefficient when only a small portion of the existing note needed updating. (reddit.com)
• Do not buy for autonomous diagnosis or treatment planning. Suki explicitly defines Ask as retrieval and synthesis, with clinician responsibility retained. (suki.ai)
• Do not sign before verifying mandatory controls. If EU residency, SCIM, customer-facing audit logs, or specific ISO certifications are required, unresolved documentation is a procurement blocker—not evidence that the controls are absent.
• Treat unclear pilot, renewal, and exit terms as red flags. Trial listings conflict, and a universal annual minimum was not verified. Require written terms rather than relying on comparison sites. (trustradius.com)

• Human review remains necessary: Draft notes, coding suggestions, and orders should not be treated as final clinical artifacts. (pmc.ncbi.nlm.nih.gov)
• Order completeness depends on encounter information: Unspoken details can require manual completion; EHR-specific structured-data differences are an acknowledged engineering challenge. (suki.ai)
• New dictation integration is narrower than overall platform marketing: The dedicated Dictation page prominently names Epic and MEDITECH and asks when additional integrations will be ready. Confirm this particular module independently of ambient-note support. (suki.ai)
• Language evidence is limited: Multilingual capability is marketed, but the reviewed note-quality study excluded non-English encounters. (suki.ai)
• Specialty evidence is limited: Five specialties in one quality study do not validate performance across the full advertised range. (pubmed.ncbi.nlm.nih.gov)
• API operational specifications remain unclear: Publicly established rate limits, quotas, versioning guarantees, sandbox terms, and per-call prices were not found.
• Scale and reliability are not quantified: No verified maximum concurrency, sustained-throughput threshold, latency SLA, or uptime history was established.

• Additional ambient order types and EHR support are described as ongoing expansion, without public completion dates. (suki.ai)
• Ask’s future content sources, calculators, guidelines, and task-completion agents are roadmap statements, not proof of present availability. (suki.ai)
• Series E funding is intended partly to support agentic workflows such as referrals and scheduling; the financing announcement does not establish general availability of those functions. (inc.com)

Bottom line: Suki has customer evidence and a broad workflow proposition beyond transcription. Its strongest buying case is successful integration plus demonstrable clinician-level time savings. Its weakest evidence concerns universal accuracy, uniform ROI, and applicability across every specialty and module. A controlled pilot with explicit safety, utilization, editing-time, and cost thresholds is the appropriate purchasing test. (klasresearch.com)

• Multiple documentation approaches: Ambient capture, dictation, and editing within one product family can accommodate differing clinician preferences. The concierge-practice interview supports practical value from this flexibility. (elion.health)
• Integration-led value: Positive Oracle/Cerner and Epic customer feedback supports the possibility of useful integrated workflows, although not universal reliability. (apps.apple.com)
• Embedded platform business: APIs and SDKs provide a distinct route for healthcare software vendors to incorporate Suki without adopting its first-party interface. (suki.ai)
• Chart-aware evidence retrieval: Ask combines chart context with UpToDate content. Its general release is described in October 2026 materials, but preference evaluations lack publicly disclosed sample and benchmark detail. (suki.ai)

The supplied page’s claims of being “most embedded,” that “no other platform comes close,” and “infinitely scalable” lack disclosed comparative methodology. No independently verified exclusive feature was established. Microsoft offers ambient plus dictation, and Freed offers coding and patient materials at higher tiers. Suki’s advantage is better framed as a particular combination of capabilities and integration relationships—not uniqueness of each capability. (support.microsoft.com)

G2 counts changed between indexed and live results; the live seller-page snapshot is reported rather than combining inconsistent snapshots. Some displayed reviews were explicitly incentivized, and one reviewer’s profile identified a chemical-engineering role rather than clinical practice. This weakens their usefulness for validating clinical performance. (G2 seller page snapshot)

• G2, Yash C., September 2, 2026, incentivized review: “What I like best about Suki Assistant is its ability to reduce documentation work and save time.” The individual star rating was not preserved in accessible text. (G2 seller page)
• Apple App Store, SusanYL, May 20, 2025: “Intuitive to use, excellent support and seamless integration into Cerner Powerchart.” This supports workflow and support satisfaction, but is one user’s experience. (Apple App Store listing)
• Reddit, u/bassejm0, July 20, 2025: “Overall, it has been life changing for me and a huge time saver.” The same user also acknowledged unresolved “kinks” and uncertainty about employer-paid cost. (Reddit thread)

• Capterra, ALTON J N., owner/provider in mental healthcare, April 1, 2024, low-rated review: “For the past several months the program became glitchy.” The reviewer described text deletion/reinsertion, insertion of prior dictated material, brief cursor disruptions, reduced accuracy, and stopping use. This is a historical dictation complaint—not proof that the same defect persists today. (Capterra listing)
• Apple App Store, Simuser, February 20, 2025: “The notes are generic and repetitive.” The oncology reviewer also reported drug-recognition failures, omitted detail, and confusion between speakers and note sections despite a month working with the Suki team. Individual star labels were not recoverable. (Apple App Store listing)
• Reddit, u/Countenance, October 31, 2024, complete comment:

I've used Suki. Hated it. Fun for the HPI but for the A/P produced this bloated paragraph format that's probably cool looking to patients but useless for other providers except for really simple problems. The main issue was honestly the rest of the software. It took too long to pull over and with that time plus reviewing the note and editing it for clairty I'm actually faster without it.

This account directly challenges whether note generation produces net time savings after transfer, review, and correction. (Reddit thread)

• Why customers select Suki: Integrated charting, reduced typing, rapid draft availability, and flexibility between dictation and ambient workflows recur in accessible accounts. An interview with a COO at a multi-provider concierge practice described choosing Suki over iScribe because human editing had become expensive and slow. (Vendor review site interview)
• Confirmed discontinuation: The Capterra reviewer explicitly stopped using Suki. A subsequent replacement vendor was not identified. (Capterra listing)
• Potential deal-breakers: Specialty terminology failures, cumbersome assessment-and-plan output, insufficient net time savings, and unconfirmed pricing or trial terms. These are supported concerns, not measured market-wide churn drivers. (Apple App Store listing)

High-star feedback exists in G2’s distribution, and a documented low-star review is included with comparable analytical attention. Individual positive review ratings could not be reliably recovered, so no quotation is falsely labeled as a high-star review.

KLAS published a Suki ROI validation on January 22, 2026, confirming deployments and positive documentation and financial outcomes at these three organizations. The underlying KLAS dataset requires login; the figures below therefore come from Suki’s published summary rather than direct inspection of the complete KLAS analysis. (KLAS report summary and vendor blog synopsis)

The variation is material: Rush’s reported revenue improvement was far below the vendor homepage’s published average. The summary describes clinician champions, advanced governance, and longitudinal measurement as adoption enablers. McLeod reportedly achieved high adoption among a few hundred providers. Nevertheless, causal attribution, all-in costs, payer adjustments, and confidence intervals could not be independently inspected. Higher billing levels are not by themselves proof of improved coding accuracy. (Vendor blog synopsis of KLAS results)

A quality-improvement poster authored by Rush describes an August 2024 launch, data through early 2025, a few hundred enrolled participants, about one hundred clinicians eligible for EHR analysis, a few dozen survey respondents, and several interviews. Thousands of notes were generated during the first several months. High utilizers saved several additional minutes daily in notes versus minimal savings for low utilizers; their progress notes increased in length. (Quality-improvement poster from the health system)

Feedback was mixed: some clinicians valued patient engagement and reduced stress, while many interviewees still reported heavy editing for excessive wordiness or insufficient assessment-and-plan detail. The authors characterized practical gains as modest. This poster is a useful counterweight to promotional results, although it is a nonrandomized report with small feedback samples and self-selection by utilization. (Quality-improvement poster from the health system)

An Elion COO interview describes a multi-state, several-dozen-provider practice switching from iScribe. Some physicians previously incurred substantial monthly editing fees, with about one-day turnaround. Suki’s then-bundled enhanced review reportedly returned notes within hours at lower cost. (Customer interview on vendor review page)

This is a concrete purchasing rationale, but reflects an older service configuration rather than proof of current ambient-only economics. Exact Suki contract cost, organization identity, and comparative accuracy were not disclosed in the accessible excerpt.

The following ranges are analyst qualification guidance, not measured customer-distribution data.

Named examples include FMOL Health, McLeod Health, and Rush, whose deployments are substantiated by a KLAS report rather than customer logos alone. A small concierge practice supplies evidence of a smaller-group use case. (KLAS report)

• Highly efficient clinicians with little documentation burden to remove.
• Specialty terminology repeatedly missed during real encounters.
• Low expected utilization under fixed-license pricing.
• Workflows requiring offline operation, customer-controlled deployment, or unverified residency options.
• Buyers expecting autonomous clinical decisions or unsigned order execution.

These are purchasing criteria derived from observed variability, not claims that all such deployments fail. (Industry poster/whitepaper)

• Provider organizations: Medical groups, ambulatory practices, hospitals, and health systems seeking to reduce documentation burden within existing EHR workflows.
• Individual clinicians: Physicians and advanced practice clinicians who need ambient notes, dictation, and editing assistance, although current marketing is predominantly sales-led.
• Technology partners: EHR, telehealth, care-management, and other healthcare software companies embedding Suki capabilities. Partner access is requested rather than presented as unrestricted self-service API access. (Vendor partner page)